SCHEMBL23833409

SCHEMBL23833409

COc1ncc(NC(=O)c2ccc3c(c2)n(C)c(=O)n3C)cc1S(=O)(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.53
TP53 P04637 3/20 0.52
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
ATM Q13315 1/20 0.48
BRPF1 P55201 2/20 0.46
BRD4 O60885 1/20 0.46
MAPT P10636 5/20 0.45
HTT P42858 3/20 0.45
KCNJ1 P48048 1/20 0.44
KCNH2 Q12809 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.43
NR0B1 P51843 1/20 0.43
ALDH1A1 P00352 2/20 0.43
KDM4E B2RXH2 2/20 0.43
LMNA P02545 2/20 0.43
MITF O75030 1/20 0.43
MAPK1 P28482 1/20 0.43
EGFR P00533 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30151054 1.00 SMN1; SMN2 (0.53) SMN1; SMN2TP53MEN1KMT2AATM
SCHEMBL23846621 0.82 MEN1 (0.54) SMN1; SMN2TP53MEN1KMT2AATM
SCHEMBL23833405 0.82 MAPT (0.53) SMN1; SMN2TP53MEN1KMT2AMAPT
SCHEMBL23833436 0.81 MEN1 (0.46) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL30151099 0.81 MEN1 (0.46) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL23840308 0.80 MEN1 (0.46) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL23833438 0.77 DRD2 (0.47) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL30151019 0.77 DRD2 (0.47) SMN1; SMN2MEN1KMT2AMAPTHTT
SCHEMBL23840640 0.77 BRD4 (0.49) TP53BRD4KCNJ1KCNH2ALPL
SCHEMBL23833492 0.76 KDM4E (0.59) SMN1; SMN2MEN1KMT2AMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121030-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF Amathus Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
WO-2021188907-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159509-A1 PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, PPM1D SMN1; SMN2 428/4885TP53 20/4885MEN1 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.